Status:
RECRUITING
POlycythemia, Proteins and ErYthropoiesis
Lead Sponsor:
Centre Hospitalier Universitaire Dijon
Conditions:
Erythropoiesis
Eligibility:
All Genders
18+ years
Brief Summary
Erythropoiesis encompasses all the stages and mechanisms involved in the production of red blood cells, or erythrocytes, under the control of a large number of regulatory agents, most often proteins. ...
Eligibility Criteria
Inclusion
- \- Persons who have given their non-opposition
- Patients with polycythemia:
- haemoglobin value \> 16 g/dl female or \> 16.5 g/dl male
- with a well-identified cause: either primary (polycythemia Vaquez, erythropoietin receptor or LNK/SH2B3 mutation...) or secondary \[cardio-respiratory pathologies, renal pathologies (post-transplant, polycystic kidney disease), metabolic pathologies, tumour (leiomyoma, pheochromocytoma...), constitutional mutations (hyperaffine haemoglobins, HIF2/EPAS1, PHD/EGLN1, VHL, ...)
- Patients control:
- \- persons with a similar pathology to that of polycythemia patients, essentialy secondary, but without polycythemia, i.e. with a haemoglobin value of \< 16 g/DL for women and \< 16.5 g/DL for men
Exclusion
- Person subject to a measure of legal protection (guardianship, tutorship)
- Person subject to a court order
- Pregnant, parturient or nursing woman
- Incapable of expressing consent
- Minor
Key Trial Info
Start Date :
September 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2028
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT06905106
Start Date
September 1 2024
End Date
September 1 2028
Last Update
April 1 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Dijon Bourgogne
Dijon, France, 21000